These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 16415123

  • 1. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).
    Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Völker U, Kroemer HK.
    Drug Metab Dispos; 2006 Apr; 34(4):524-33. PubMed ID: 16415123
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.
    Cancer Lett; 2009 Jun 28; 279(1):74-83. PubMed ID: 19232821
    [Abstract] [Full Text] [Related]

  • 5. Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase.
    Imai Y, Ohmori K, Yasuda S, Wada M, Suzuki T, Fukuda K, Ueda Y.
    Cancer Sci; 2009 Jun 28; 100(6):1118-27. PubMed ID: 19514121
    [Abstract] [Full Text] [Related]

  • 6. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.
    Oncotarget; 2015 Dec 29; 6(42):44643-59. PubMed ID: 26556876
    [Abstract] [Full Text] [Related]

  • 7. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A, Wiese M.
    ChemMedChem; 2012 Apr 29; 7(4):650-62. PubMed ID: 22354538
    [Abstract] [Full Text] [Related]

  • 8. Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.
    Xie Y, Nakanishi T, Natarajan K, Safren L, Hamburger AW, Hussain A, Ross DD.
    Biochim Biophys Acta; 2015 Mar 29; 1849(3):317-27. PubMed ID: 25615818
    [Abstract] [Full Text] [Related]

  • 9. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F.
    Clin Exp Pharmacol Physiol; 2006 Mar 29; 33(1-2):58-65. PubMed ID: 16445700
    [Abstract] [Full Text] [Related]

  • 10. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors.
    Evseenko DA, Paxton JW, Keelan JA.
    Drug Metab Dispos; 2007 Apr 29; 35(4):595-601. PubMed ID: 17237156
    [Abstract] [Full Text] [Related]

  • 11. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS.
    Cancer Res; 2007 Nov 15; 67(22):11012-20. PubMed ID: 18006847
    [Abstract] [Full Text] [Related]

  • 12. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):594-600. PubMed ID: 16520985
    [Abstract] [Full Text] [Related]

  • 13. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
    Darby RA, Unsworth A, Knapp S, Kerr ID, Callaghan R.
    Cancer Chemother Pharmacol; 2015 Oct 15; 76(4):853-64. PubMed ID: 26351135
    [Abstract] [Full Text] [Related]

  • 14. The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction.
    Evseenko DA, Murthi P, Paxton JW, Reid G, Emerald BS, Mohankumar KM, Lobie PE, Brennecke SP, Kalionis B, Keelan JA.
    FASEB J; 2007 Nov 15; 21(13):3592-605. PubMed ID: 17595345
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin.
    Smith PC, Santibañez JF, Morales JP, Martinez J.
    J Periodontal Res; 2004 Dec 15; 39(6):380-7. PubMed ID: 15491342
    [Abstract] [Full Text] [Related]

  • 16. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N, Yuan J, Liu J, Tian S.
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec 15; 42(12):854-62. PubMed ID: 21106767
    [Abstract] [Full Text] [Related]

  • 17. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
    Imai Y, Ishikawa E, Asada S, Sugimoto Y.
    Cancer Res; 2005 Jan 15; 65(2):596-604. PubMed ID: 15695404
    [Abstract] [Full Text] [Related]

  • 18. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM.
    Arch Otolaryngol Head Neck Surg; 2007 Oct 15; 133(10):1022-7. PubMed ID: 17938326
    [Abstract] [Full Text] [Related]

  • 19. Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines.
    Tomiyasu H, Watanabe M, Sugita K, Goto-Koshino Y, Fujino Y, Ohno K, Sugano S, Tsujimoto H.
    Anticancer Res; 2013 Dec 15; 33(12):5317-23. PubMed ID: 24324065
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE.
    Clin Cancer Res; 2001 Jan 15; 7(1):145-52. PubMed ID: 11205902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.